Chr. Hansen and Glycom settle HMO patent disputes inherited from Jennewein acquisition

Related Articles

FormattedPicture

BUSINESS NEWS

Chr. Hansen is reporting a “stronger-than-expected” start for its Human Health business in its Q1 2021/2022 results. The Denmark-based company says this is... Read More

FormattedPicture

FOOD INGREDIENTS NEWS

A panel of industry experts selected Chr. Hansen’s FreshQ concept at this year’s Fi Europe Innovation Awards in Frankfurt, Germany. The Food Tech Innovation... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

Rousselot, a Darling Ingredients’ health brand, has been granted a patent application by the European Patent Office (EPO) for its functional gummies gelatin-based... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

Chr. Hansen is launching a new program aiming to reduce its carbon footprint by 2030, named “Think Climate. Naturally.”

FormattedPicture

BUSINESS NEWS

Chr. Hansen and Lonza’s joint venture Bacthera and microbiome therapeutics company Seres Therapeutics are teaming up to manufacture SER-109, Seres’ lead... Read More

trans